403 related articles for article (PubMed ID: 24053906)
1. Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer.
Rieken M; Xylinas E; Kluth L; Crivelli JJ; Chrystal J; Faison T; Lotan Y; Karakiewicz PI; Fajkovic H; Babjuk M; Kautzky-Willer A; Bachmann A; Scherr DS; Shariat SF
BJU Int; 2013 Dec; 112(8):1105-12. PubMed ID: 24053906
[TBL] [Abstract][Full Text] [Related]
2. Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma.
Rieken M; Xylinas E; Kluth L; Crivelli JJ; Chrystal J; Faison T; Lotan Y; Karakiewicz PI; Sun M; Fajkovic H; Babjuk M; Bachmann A; Scherr DS; Shariat SF
Urol Oncol; 2014 Jan; 32(1):49.e7-14. PubMed ID: 24140245
[TBL] [Abstract][Full Text] [Related]
3. Diabetes mellitus without metformin intake is associated with worse oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma.
Rieken M; Xylinas E; Kluth L; Trinh QD; Lee RK; Fajkovic H; Novara G; Margulis V; Lotan Y; Martinez-Salamanca JI; Matsumoto K; Seitz C; Remzi M; Karakiewicz PI; Scherr DS; Briganti A; Kautzky-Willer A; Bachmann A; Shariat SF;
Eur J Surg Oncol; 2014 Jan; 40(1):113-20. PubMed ID: 24113620
[TBL] [Abstract][Full Text] [Related]
4. The long-term outcome of treated high-risk nonmuscle-invasive bladder cancer: time to change treatment paradigm?
Thomas F; Rosario DJ; Rubin N; Goepel JR; Abbod MF; Catto JW
Cancer; 2012 Nov; 118(22):5525-34. PubMed ID: 22544645
[TBL] [Abstract][Full Text] [Related]
5. The effect of metformin on cancer-specific survival outcomes in diabetic patients undergoing radical cystectomy for urothelial carcinoma of the bladder.
Nayan M; Bhindi B; Yu JL; Hermanns T; Mohammed A; Hamilton RJ; Finelli A; Jewett MA; Zlotta AR; Fleshner NE; Kulkarni GS
Urol Oncol; 2015 Sep; 33(9):386.e7-13. PubMed ID: 26097049
[TBL] [Abstract][Full Text] [Related]
6. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
[TBL] [Abstract][Full Text] [Related]
7. Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer.
Thomas F; Noon AP; Rubin N; Goepel JR; Catto JW
Eur Urol; 2013 Jan; 63(1):145-54. PubMed ID: 22985746
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of renin-angiotensin system blockade in non-muscle-invasive bladder cancer.
Yuge K; Miyajima A; Tanaka N; Shirotake S; Kosaka T; Kikuchi E; Oya M
Ann Surg Oncol; 2012 Nov; 19(12):3987-93. PubMed ID: 22872290
[TBL] [Abstract][Full Text] [Related]
9. Construction of predictive models for recurrence and progression in >1000 patients with non-muscle-invasive bladder cancer (NMIBC) from a single centre.
Ali-El-Dein B; Sooriakumaran P; Trinh QD; Barakat TS; Nabeeh A; Ibrahiem el-HI
BJU Int; 2013 Jun; 111(8):E331-41. PubMed ID: 23445082
[TBL] [Abstract][Full Text] [Related]
10. Polyamine-modulated factor-1 methylation predicts Bacillus Calmette-Guérin response in patients with high-grade non-muscle-invasive bladder carcinoma.
Alvarez-Múgica M; Fernández-Gómez JM; Cebrian V; Fresno F; Escaf S; Sánchez-Carbayo M
Eur Urol; 2013 Feb; 63(2):364-70. PubMed ID: 22682992
[TBL] [Abstract][Full Text] [Related]
11. Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non-muscle invasive bladder cancer.
Fahmy M; Mansure JJ; Brimo F; Yafi FA; Segal R; Althunayan A; Hicks J; Meeker A; Netto G; Kassouf W
Hum Pathol; 2013 Sep; 44(9):1766-72. PubMed ID: 23623586
[TBL] [Abstract][Full Text] [Related]
12. Association of metformin intake with bladder cancer risk and oncologic outcomes in type 2 diabetes mellitus patients: A systematic review and meta-analysis.
Hu J; Chen JB; Cui Y; Zhu YW; Ren WB; Zhou X; Liu LF; Chen HQ; Zu XB
Medicine (Baltimore); 2018 Jul; 97(30):e11596. PubMed ID: 30045293
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer.
Kim EJ; Lee YS; Kim YJ; Kim MJ; Ha YS; Jeong P; Lee OJ; Kim WJ
Urology; 2010 Jun; 75(6):1516.e9-13. PubMed ID: 19913893
[TBL] [Abstract][Full Text] [Related]
14. Predictors of cancer-specific mortality after disease recurrence following radical cystectomy.
Rink M; Lee DJ; Kent M; Xylinas E; Fritsche HM; Babjuk M; Brisuda A; Hansen J; Green DA; Aziz A; Cha EK; Novara G; Chun FK; Lotan Y; Bastian PJ; Tilki D; Gontero P; Pycha A; Baniel J; Mano R; Ficarra V; Trinh QD; Tagawa ST; Karakiewicz PI; Scherr DS; Sjoberg DD; Shariat SF;
BJU Int; 2013 Mar; 111(3 Pt B):E30-6. PubMed ID: 22938654
[TBL] [Abstract][Full Text] [Related]
15. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study.
Masoudi FA; Inzucchi SE; Wang Y; Havranek EP; Foody JM; Krumholz HM
Circulation; 2005 Feb; 111(5):583-90. PubMed ID: 15699279
[TBL] [Abstract][Full Text] [Related]
16. Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non-muscle-invasive bladder cancer.
Mano R; Baniel J; Shoshany O; Margel D; Bar-On T; Nativ O; Rubinstein J; Halachmi S
Urol Oncol; 2015 Feb; 33(2):67.e1-7. PubMed ID: 25060672
[TBL] [Abstract][Full Text] [Related]
17. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
[TBL] [Abstract][Full Text] [Related]
18. Diabetes mellitus with poor glycemic control increases bladder cancer recurrence risk in patients with upper urinary tract urothelial carcinoma.
Tai YS; Chen CH; Huang CY; Tai HC; Wang SM; Pu YS
Diabetes Metab Res Rev; 2015 Mar; 31(3):307-14. PubMed ID: 25363092
[TBL] [Abstract][Full Text] [Related]
19. The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy.
Linder BJ; Frank I; Cheville JC; Tollefson MK; Thompson RH; Tarrell RF; Thapa P; Boorjian SA
Eur Urol; 2013 May; 63(5):839-45. PubMed ID: 23332883
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]